References
- Chen M, Zhang M, Borlak J, et al. A decade of toxicogenomic research and its contribution to toxicological science. Toxicol Sci. 2012;130(2):217–228.
- Afshari CA, Hamadeh HK, Bushel PR. The evolution of bioinformatics in toxicology: advancing toxicogenomics. Toxicol Sci. 2011;120 Suppl 1:S225–S237.
- Boverhof DR, Zacharewski TR. Toxicogenomics in risk assessment: applications and needs. Toxicol Sci. 2006;89(2):352–360.
- Hendrickx DM, Boyles RR, Kleinjans JC, et al. Workshop report: identifying opportunities for global integration of toxicogenomics databases, 26–27 June 2013, Research Triangle Park, NC, USA. Arch Toxicol. 2014;88(12):2323–2332.
- Chiusolo A, Defazio R, Zanetti E, et al. Kidney injury molecule-1 expression in rat proximal tubule after treatment with segment-specific nephrotoxicants: a tool for early screening of potential kidney toxicity. Toxicol Pathol. 2010;38(3):338–345.
- Waters MD, Jackson M, Lea I. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. Mutat Res. 2010;705(3):184–200.
- Brambilla G, Martelli A. Genotoxicity and carcinogenicity studies of analgesics, anti-inflammatory drugs and antipyretics. Pharmacol Res. 2009;60(1):1–17.
- Dalmas DA, Scicchitano MS, Mullins D, et al. Potential candidate genomic biomarkers of drug induced vascular injury in the rat. Toxicol Appl Pharmacol. 2011;257(2):284–300.
- Fielden MR, Adai A, Dunn RT, et al. Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat. Toxicol Sci. 2011;124(1):54–74.
- McMillian M, Nie AY, Parker JB, et al. Inverse gene expression patterns for macrophage activating hepatotoxicants and peroxisome proliferators in rat liver. Biochem Pharmacol. 2004;67(11):2141–2165.
- Goodsaid FM, Amur S, Aubrecht J, et al. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov. 2010;9(6):435–445.
- Khan SR, Baghdasarian A, Fahlman RP, et al. Current status and future prospects of toxicogenomics in drug discovery. Drug Discov Today. 2014;19(5):562–578.
- Thomas RS, Philbert MA, Auerbach SS, et al. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci. 2013;136(1):4–18.
- Sandhu KS, Veeramachaneni V, Yao X, et al. Release of (and lessons learned from mining) a pioneering large toxicogenomics database. Pharmacogenomics. 2015;16(8):779–801.
- Sistare FD, DeGeorge JJ. Applications of toxicogenomics to nonclinical drug development: regulatory science considerations. In: Mendrick DL, Mattes WB, editor. Methods in molecular biology. Totowa (NJ):Humana Press. Vol. 460. 2008. pp. 239–261.